Top Markets
Coin of the day
Decision Diagnostics Corp. Decision Diagnostics Corp.

Decision Diagnostics Corp.

DECN
Pozycja w akcjach #41198
Decision Diagnostics Corp. (DECN), founded in 2000 and based in Westlake... Decision Diagnostics Corp. (DECN), founded in 2000 and based in Westlake Village, California, specializes in developing electronic medical record (EMR) technologies primarily optimized for smartphones. The company provides a wide array of offerings, including both regulated and unregulated diagnostic solutions, as well as home-use testing products for individuals managing chronic illnesses. They also facilitate direct-to-patient logistics for diabetes programs and concentrate on creating mobile-centric e-health products and associated technological innovations. A key part of their product line involves glucose monitoring. This includes the GenUltimate! glucose test strips, classified as a Class II medical device for personal at-home human use. For animal health, they manufacture PetSure! glucose test strips, designed to measure glucose levels in dogs and cats and compatible with legacy Zoetis AlphaTrak glucometers. Additionally, they offer the proprietary GenUltimate! 4Pets Glucose system, which combines the GenUltimate! 4Pets strip with the Avantage meter, enabling glucose testing for canine, feline, and equine patients. Further glucose strip options include GenUltimate! Sure and GenUltimate! Precis. Beyond product development, Decision Diagnostics actively acquires and maintains a portfolio of intellectual property, spanning patents, trademarks, and specialized manufacturing equipment. Their software solutions include MD@Hand, a comprehensive management system for both inpatient and outpatient care; Practice Probe, a data mining utility designed to extract information from physician practice management systems; and ResidenceWare, a residential management system that streamlines communication between commercial or residential real estate managers and their tenants through networked applications. Ultimately, their EMR innovations provide crucial tools for physicians directly at the point of patient care. The company was originally known as InstaCare Corp. before officially changing its name to Decision Diagnostics Corp. in November 2011.
Cena akcji
$0.0001
Ostatnia synchronizacja: 2026-08-11
Kapitalizacja rynkowa
$35.79K
Zmiana (1 dzień)
0.00%
Zmiana (1 rok)
0.00%
Kraj
US
Handel Decision Diagnostics Corp. (DECN)

Kategoria

Marża operacyjna dla Decision Diagnostics Corp. (DECN)
Marża operacyjna na dzień 2026 TTM: 0.00%
Według najnowszych raportów finansowych i ceny akcji Decision Diagnostics Corp., bieżąca marża operacyjna (TTM) wynosi 0.00%. Na koniec 2026 wynosiła 0.00%.
Historia marży operacyjnej dla Decision Diagnostics Corp. od 2026 do 2026
Marża operacyjna na koniec każdego roku
Rok Marża operacyjna Zmień
Za mało danych dla podanych dat.
Marża operacyjna dla podobnych firm lub konkurentów
Firma Marża operacyjna Różnica w marży operacyjnej Kraj
67.93% -
US
0.00% -
SE
0.00% -
FR
0.00% -
IT
0.77% -
US
Czym jest marża operacyjna firmy?
Marża operacyjna to kluczowy wskaźnik do oceny rentowności firmy. Wyższe marże operacyjne są zazwyczaj korzystniejsze, ponieważ pokazują, że firma może sprzedawać swoje produkty lub usługi znacznie drożej niż koszty ich produkcji. Oblicza się ją, dzieląc zysk firmy przez jej przychody.